Important announcement concerning Temple Health and Keystone First. Our provider agreement with Keystone First is scheduled to end on July 31st. Click the link below to learn about your options for continuing care at Temple Health.

Learn More
800-TEMPLE-MED Schedule Appointment
Back To Doctor Search

J. Nicholas Bodor, MD, PhD, MPH


Thoracic Medical Oncology

Loading ...
About Me
Ratings & Reviews
About Me
No video provider was found to handle the given URL. See the documentation for more information.
  • Philadelphia Magazine Top Doctors, 2024
  • ASCO Annual Meeting Merit Award American Society of Clinical Oncology Chicago, IL, 2018

Office Locations

Fox Chase Cancer Center

333 Cottman Avenue

Philadelphia, PA 19111

Phone: 888-369-2427

  1. O'Brien J, Bodor JN. Perioperative Immunotherapy in Non-Small Cell Lung Cancer. Curr Treat Options in Oncol. 2023 Dec 13. Online ahead of print.
  2. Bodor JN, Patel JC, Wakelee HA, Levy BP, Borghaei H, Pellini B, Costello MR, Dowell JE, Finley G, Huang CH, Neal JW, Nieva JJ, Puri S, Socinski MA, Thomas C, Ross EA, Litwin S, Clapper ML, Treat J. Phase II Randomized trial of carboplatin, pemetrexed, and bevacizumab with and without atezolizumab in stage IV non-squamous non-small cell lung cancer patients who harbor a sensitizing EGFR mutation or have never smoked. Clin Lung Cancer. 2023 24(7); e242-e246
  3. Bodor JN, Bauman JR, HandorfEA, Ross EA, Clapper ML, Treat J. Real-world progression-free survival (rwPFS) and the impact of PD-LI and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy. J Cancer Res Clin Oncol. 2023 149(5):1755-1763.
  4. Hsu R, Baca Y, Xiu J, Wang R, Bodor JN, Kim C, Khan H, Mamdani H, Nagasaka M, Puri S, Liu SV, Korn WM, Nieva JJ. Molecular characterization of Kita-Kyushu lung cancer antigen (KK-LC-1) expressing carcinomas. Oncotarget. 2021 12(25):2449-2458.
  5. Salem ME, Bodor JN, Puccini A, Xiu J, Goldberg RM, Grothey A, Korn WM, Shields AF. Worrilow WM, Kim ES, Lenz HJ, Marshall JL, Hall MJ. Relationship between MLHl, PMS2, MSH2, and MSH6 gene specific alterations and tumor mutational burden {TMB) in 1,057 microsatellite instability-high solid tumors. Int J Cancer. 2020 May 24. doi: 10.1002/ijc.33l l 5.
  6. Bodor JN, Boumber Y, Borghaei H. Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC). Cancer 2020 126:260-270.
  7. Bodor JN, Feliciano JL, Edelman MJ. Outcomes of patients with disease recurrence after treatment for locally advanced non-small cell lung cancer detected by routine follow-up CT scans versus a symptom driven evaluation. Lung Cancer 2019 135:16-20
  8. Bodor JN, Kasireddy V, Borghaei H. First-line therapies for metastatic lung adenocarcinoma without a driver mutation. J Oncol Pract. 2018 Sep;14:529-535.
  9. Winer A, Bodor JN, Borghaei H. Identifying and managing the adverse effects of immune checkpoint blockade. J Thorac Dis. 2018; 10 (Suppl 3):S480-S489.
  10. Bodor JN, Hutchison PL, Rose D. Car ownership and the association between fruit and vegetable availability and diet. Preventive Medicine 2013;57:903-905.
  11. Bodor JN, Rice JC, Farley TA, Swaim CM, Rose D. The association between obesity and urban food environments. Journal of Urban Health 2010;87:771-81.
  12. Bodor JN, Rice JC, Farley TA, Swaim CM, Rose D. Disparities in food access: Does aggregate availability of key foods from other stores offset the relative lack of supermarkets in African-American neighborhoods? Preventive Medicine 2010;51:63-7.
Ratings & Reviews

The following ratings and reviews are based on verified feedback collected from independently administered patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions. Patient identities are withheld to ensure confidentiality and privacy. Learn more about our Patient Experience Ratings.

Ratings Breakdown

Loading ...

Patient Comments

Loading ...